IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability

Autor: Rogelio del Pino Algarrada, Angel Leon-Valenzuela, Juan Sánchez Palacios

Publikováno v: BMC Neurology, Vol 20, Iss 1, Pp 1-6 (2020)
León-Valenzuela, A., Palacios, J.S. & del Pino Algarrada, R. IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability. BMC Neurol 20, 126 (2020). https://doi.org/10.1186/s12883-020-01702-7
BMC Neurology
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
instname

Background: IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with established efficacy in the treatment of upper-limb spasticity in adults. This retrospective case series in a university hospital setting aimed to elucidate the safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8245ef8d3834b16268e80e3f9777309b
http://link.springer.com/article/10.1186/s12883-020-01702-7

IncobotulinumtoxinA for the treatment of spasticity in children with cerebral palsy – a retrospective case series focusing on dosing and tolerability

Autor: Angel León-Valenzuela, Juan Sánchez Palacios, Rogelio del Pino Algarrada

Publikováno v: BMC Neurology, Vol 20, Iss 1, Pp 1-6 (2020)

Abstract Background IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with established efficacy in the treatment of upper-limb spasticity in adults. This retrospective case series in a university hospital setting aimed to elucidate the

Externí odkaz: https://doaj.org/article/02f446848c634b9aba7a649dd9c02bf9